Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 12.78% | 13.46% | 11.99% | 11.61% | 24.59% |
Total Depreciation and Amortization | -5.09% | -9.19% | -9.59% | -6.85% | -2.45% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -36.77% | -18.17% | -18.07% | -15.49% | 0.90% |
Change in Net Operating Assets | 33.50% | 27.55% | 22.95% | 18.65% | -128.14% |
Cash from Operations | 17.46% | 18.27% | 14.99% | 13.44% | 2.34% |
Capital Expenditure | -253.59% | -20.90% | 25.98% | 68.13% | 86.09% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -200.00% | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -70.59% | -118.75% | -119.91% | -114.06% | -22.49% |
Cash from Investing | -71.49% | -119.43% | -120.70% | -114.73% | -21.49% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -98.27% | 3,592.75% | 5,862.49% | 6,504.17% | 19,059.03% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -100.00% | -- | -- | -- | -- |
Cash from Financing | -98.63% | 3,572.18% | 5,829.58% | 6,467.79% | 19,023.83% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -179.80% | -163.70% | -188.48% | 27.10% | 2,402.83% |